From FB with Joe's permission:
Here is my synopsis on
From FB with Joe's permission:
Here is my synopsis on the vaccines not approved by FDA but cleared for emergency use from small patient sampling’s from 40/60 thousand phase 3 trials, this is a hard rude awakening people.
We expect side effects from mRNA vaccines will become more prevalent over time and the weaknesses of mRNA vaccine technology will be exposed. Efficacy and side effect profiles observed in tightly controlled clinical trials often vary from real-world results, especially when trials are limited in scope and duration for accelerated EUA approval by a government(s) desperate. In the case of COVID-19 mRNA vaccine trials, close examination of evidence suggests side effects observed in the clinical trials were downplayed or outright ignored. The best example of this is Bell’s Palsy.
In Pfizer’s trial 4 patients experienced “Bell’s Palsy” with 0 (zero) in the placebo group. In Moderna’s trial 3 patients experienced “Bell’s Palsy” with 1 in the placebo group. The FDA concluded that the “Bell’s Palsy” was not attributable to the vaccines because the event rates were similar to that seen in the general population. This logic is inconsistent with standard data interpretation and risk assessment because “Bell’s Palsy” occurred at a 400% higher rate in Pfizer’s trial and 300% higher rate in Moderna’s trial. Under normal circumstances this might have stopped the trials but under EUA it was ignored. But it gets worse... Bell’s Palsy by definition is temporary facial paralysis that completely resolves. Upon trial conclusion and FDA approval, 3 of the 4 cases in Pfizer’s trial were unresolved and 2 of the 3 cases in Moderna’s trial were unresolved (a combined 71.4% remained unresolved). The true and correct medical diagnosis at the time of FDA approval was facial paralysis. Only after paralysis resolves can it be diagnosed as Bell’s Palsy. It’s deceitful and negligent to label unresolved facial paralysis as Bell’s Palsy and was obviously done to downplay the risk and avoid reporting severe adverse events.
We suspect the facial paralysis could have been caused by non-neutralizing antibodies generated by the mRNA vaccines. Only a very small fraction of total antibodies generated from mRNA vaccines are neutralizing. The vast majority are non-neutralizing and pose a potential risk for harmful off-target binding, side effects, and autoimmunity. mRNA vaccines cannot predict or control antigen processing and presentation (i.e. how the Spike protein will be internalized by antigen processing cells, digested into peptides, processed and loaded onto MHC, and presented to the immune system for antibody production). This is a largely random process and peptides-antibodies can vary with each vaccine and booster and vary from person to person. With Generex’s Ii-Key-SARS-CoV-2 vaccine, we know exactly what peptides are being introduced. We know these peptides are being delivered in original pure form directly to MHC because Ii-Key bypasses the natural antigen processing system. Furthermore, using our computational vaccinology programs, we know our peptide sequences do not exist in the human body and harmful off-target antibody binding is not possible. We don’t use 1791 non neutralizing antibodies that Skew also very harmful Th2 from the very bad spike protein, we use only use the best and safest parts, in addition these parts are in all variants.
2
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Why Jereh Saturn Is a Game-Changer Imagine cutting down months, if not years, of setup time in a sector that's notoriously slow-moving. That's exactly what Jereh’s new Saturn Modular Gas Gensets promise. Rolled out in Yantai, China, these power units are all about efficiency and speed—right off the bat they bring immediate juice to oil and gas fields as well as...
Continue Reading
Foxconn's Bold Step into AI Infrastructure Foxconn, the tech giant that most folks recognize for its sheer prowess in electronics manufacturing, isn't just idling on past laurels. During the 7th annual Hon Hai Tech Day 2026, it was a showcase of fireworks that left attendees buzzing about the future of AI infrastructure and beyond. And when Foxconn says it's transforming,...
Continue Reading
Foxconn Boldly Claims New Ground in EV Market Foxconn's at it again, thumping its chest in the electric vehicle arena with three fresh rides that scream ambition. At the HHTD26 in Taipei, they rolled out the MODEL A+, MODEL K+, and MODEL K—vehicles that not only diversify their portfolio but target segments that rarely see such a jolt. Does it get your gears turning?...
Continue Reading
You ever take a stroll around a trade show floor packed with folks jiving over the latest in food and wellness? That's what's going down at SupplySide Global 2026 in Las Vegas, and Samyang Corporation is strutting in with a heap of sugar reduction solutions and dietary fiber goods that would make any nutritionist grin from ear to ear. Debuting Tapioca-Based Resistant...
Continue Reading
Broadway.com's Instagram Ascends to Iconic Status There it is, folks—Broadway.com's Instagram just threw down the gauntlet with a clean, million-follower milestone. That's right, a hefty chunk of people now have a front-row seat to Broadway's electric world, straight from their phones. If you're a Broadway buff or just a casual admirer of glitz and glam, these numbers...
Continue Reading
Breathing New Life into a Brooklyn Classic Alright, picture this: You're stepping into a century-old Brooklyn loft, expecting dust, aged wood, maybe a ghost or two. What you actually find is art wrapped in brass with a splash of modern flair. This ain't just any loft, folks—it's the latest trophy on the mantle for Gallery KBNY, a design-build firm known for its...
Continue Reading
Innovating the Turkey Call Game You want innovation? Well, wrap your head around this: a Missouri inventor is flipping the script on turkey mouth calls. The goal? To ditch the wrinkles and make turkey hunting that much smoother. It might seem a bit niche, but when you've been around long enough, you know these 'niche' ideas can sometimes hatch golden eggs for investors....
Continue Reading
An Unexpected Dance of Flavors Nestled in Kanazawa’s Nishi Chaya District, Canisienne Kanazawa isn’t just another eatery—it’s an engulfing dive into the world of winter crab extravagance. Picture yourself at an intimate, eight-seat counter, where chefs transform live crabs into culinary masterpieces right before your eyes. From early November to the end of...
Continue Reading
AI Meets Full-Fidelity Document Editing Gone are the days when AI could only analyze documents. With Reducto Office's latest plugin, the AI's stepping right into the editing game. For free, they say! Built smack-dab into ChatGPT and Codex, this plugin lets users work their AI magic on Word docs, PowerPoint presentations, and Excel spreadsheets. And the kicker? You can see...
Continue Reading
Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Golub Capital BDC's Earnings Expectations Golub Capital BDC (NASDAQ: GBDC) is on the brink of releasing its latest quarterly earnings report. Investors are keen to gauge the company's financial health and overall market performance. With anticipation growing, let’s delve into what to expect from this earnings announcement. Projected Earnings Performance...
Continue Reading
Bitcoin Cash Experiences Significant Surge In the last 24 hours, Bitcoin Cash has seen a remarkable price increase of 10.97%, now valued at $354.81. This impressive growth builds upon a positive trend observed over the previous week, during which the cryptocurrency gained 8.0%, rising from $328.29. Currently, it holds an all-time high at an astonishing $3,785.82,...
Continue Reading
AI Innovations Disrupting Wealth Management Recent advancements in artificial intelligence have sent shockwaves through the wealth management sector. With the rollout of new AI capabilities by a leading fintech platform, investor worries about potential disruption have intensified. This week, we witnessed a considerable drop in wealth management and financial stocks as...
Continue Reading
Understanding the Class Action Lawsuit for Ibotta, Inc. The opportunity for investors of Ibotta, Inc. (NYSE: IBTA) to get involved in a class action lawsuit is significant. If you are among those who experienced substantial financial losses with Ibotta shares, this is a chance for you to take action. What Is the Class Action About? The class action lawsuit against Ibotta,...
Continue Reading
Introducing Vonage RCS: The Future of Business Messaging Vonage is leading a transformative shift in business communications with their new Rich Communications Services (RCS). This innovative messaging platform aims to reshape how companies engage with customers by offering secure, interactive, and vibrant communication channels. A Fresh Take on Customer Interactions...
Continue Reading